Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:: APC8015 (Provenge®)

被引：39
|
作者：
Harzstark, Andrea L. [1 ]
Small, Eric J. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
dendritic cell; immunotherapy; prostate cancer; prostatic acid phosphatase; Provenge;
D O I：
10.1517/14712598.7.8.1275
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to overcome this deficiency by delivering antigens to antigen-presenting cells under ex vivo conditions, improving dendritic cell function. APC8015 (Provenge((R)); Dendreon Corp., Seattle, WA) is a novel immunotherapeutic, which consists of autologous dendritic cells pulsed ex vivo with PA2024, a recombinant fusion protein consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase, as an immunogenic agent. A Phase III randomized clinical trial has demonstrated a survival benefit in patients with metastatic hormone-refractory prostate cancer. This review summarizes the clinical trials using APC801 5 in prostate cancer and discusses its future role in the treatment of prostate cancer.
引用
下载
收藏
页码：1275 / 1280
页数：6
相关论文
共 50 条
  • [31] Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
    Paul F. Schellhammer
    Robert M. Hershberg
    World Journal of Urology, 2005, 23 : 47 - 49
  • [32] Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second Phase 3 trial
    不详
    EJC SUPPLEMENTS, 2005, 3 (04): : 1 - 1
  • [33] Impact of anatomic site on antigen-presenting cells in cancer
    Zagorulya, Maria
    Duong, Ellen
    Spranger, Stefani
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [34] HALF-LIFE OF ANTIGEN MHC COMPLEXES ON ANTIGEN-PRESENTING CELLS (APC) IS REGULATED BY THE MICROENVIRONMENT IN-SITU
    MUELLER, K
    KYEWSKI, B
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 29 - 29
  • [35] Nasal Submucosal Administration of Antigen-Presenting Cells Induces Effective Immunological Responses in Cancer Immunotherapy
    Okamoto, Yoshitaka
    Fujikawa, Akira
    Kurosaki, Motoyoshi
    Yamasaki, Kazuki
    Sakurai, Daijyu
    Horiguchi, Shigetoshi
    Nakayama, Toshinori
    RECENT ADVANCES IN TONSILS AND MUCOSAL BARRIERS OF THE UPPER AIRWAYS, 2011, 72 : 149 - 152
  • [36] Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?
    Creusot, Remi J.
    Postigo-Fernandez, Jorge
    Teteloshvili, Nato
    DIABETES, 2018, 67 (08) : 1481 - 1494
  • [37] Erythrocytes used as tumor antigen delivery system to target antigen-presenting cells embody an innovative approach for in situ cancer immunotherapy
    Cremel, Magali
    Guerin, Nathalie
    Barthe, Quitterie
    Bourgeaux, Vanessa
    Berlier, Willy
    Horand, Francoise
    Godfrin, Yann
    CANCER RESEARCH, 2016, 76
  • [38] Nanoscale artificial antigen presenting cells for cancer immunotherapy
    Rhodes, Kelly R.
    Green, Jordan J.
    MOLECULAR IMMUNOLOGY, 2018, 98 : 13 - 18
  • [39] Generation of artificial antigen-presenting cells for the adoptive inununotherapy in cancer
    不详
    IMMUNOBIOLOGY, 2005, 210 (6-8) : 470 - 470
  • [40] Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles
    Sayour, Elias J.
    De Leon, Gabriel
    Pham, Christina
    Grippin, Adam
    Kemeny, Hanna
    Chua, Joshua
    Huang, Jianping
    Sampson, John H.
    Sanchez-Perez, Luis
    Flores, Catherine
    Mitchell, Duane A.
    ONCOIMMUNOLOGY, 2017, 6 (01):
12345